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Abstract.  ras proteins are localized to the plasma 
membrane where they are postulated to interact with 
growth factor receptors and other proximal elements in 
intracellular  cascades triggered by growth factors. The 
molecular events associated with terminal differentia- 
tion of certain  skeletal myoblasts are inhibited by 
specific polypeptide growth factors and by constitu- 
tive expression of transforming  ras oncogenes. To de- 
termine whether the inhibitory effects of ras on myo- 
genic differentiation were reversible and to investigate 
whether muscle-specific genes remained susceptible to 
ras-dependent  repression in terminally differentiated 
myotubes, the murine myoblast cell line,  C2,  was 
transfected with a plasmid containing a  mutationally 
activated human  N-ras  oncogene under transcriptional 
control of the steroid-sensitive promoter of the mouse 
mammary tumor virus long terminal  repeat.  Addition 
of dexamethasone to myoblasts bearing steroid-in- 
ducible ras oncogenes prevented myotube formation 
and induction of muscle creatine kinase and acetylcho- 
line receptors.  Inhibition of differentiation by dexa- 
methasone occurred in a dose-dependent manner and 
was a titratable function of ras expression.  In the pres- 
ence of dexamethasone, myoblasts bearing  steroid- 
inducible ras genes retained their dependence on exog- 
enous growth factors to divide and exhibited contact 
inhibition of growth at confluent densities,  indicating 
that the inhibitory effects of ras on differentiation were 
independent of cell proliferation.  Removal of dexa- 
methasone from N-ras-transfected  myoblasts led to fu- 
sion and induction of muscle-specific gene products in 
a manner  indistinguishable  from control C2 cells.  Ex- 
amination of the effects of culture media conditioned 
by ras-transfected myoblasts on differentiation of nor- 
mal C2 cells yielded no evidence for inhibition  of 
differentiation via an autocrine mechanism.  In contrast 
to the ability of N-ras  to prevent up-regulation of 
muscle-specific gene products in myoblasts, induction 
of N-ras  in terminally differentiated myotubes failed to 
extinguish muscle-specific gene expression.  Together, 
these results suggest that oncogenic ras proteins rever- 
sibly activate an intracellular  cascade that prevents es- 
tablishment of the differentiated phenotype. The inabil- 
ity of ras to extinguish muscle-specific gene 
expression in terminally differentiated myotubes also 
suggests that  ras may interfere with an early step in 
the pathway of myoblasts toward the differentiated 
state. 
T 
HE process of myogenic differentiation  involves an or- 
dered sequence of molecular events which include ces- 
sation  of cell division,  formation  of multinucleated 
myotubes, and coordinate induction  of a battery of muscle- 
specific genes encoding proteins involved in the specialized 
functions  of the  myofiber  (for  review,  see  reference  7). 
Among the gene products that are up-regulated  during myo- 
genesis are the components of the contractile  apparatus,  the 
muscle isoenzyme of creatine kinase (MCK),I and the nico- 
tinic  acetylcholine (ACh)  receptor.  The  ability of certain 
skeletal myoblasts to differentiate  is controlled in a negative 
1. Abbreviations  used in this paper:  ACh, acetylcholine; CK, creatine ki- 
nase;  FGF,  fibroblast growth factor;  HS,  horse serum;  M,  muscle tso- 
enzyme; MMTV-LTR, mouse mammary tumor virus long terminal repeat; 
TGF~  type 13 transforming growth factor. 
manner  by the extracellular  concentration  of serum mito- 
gens, fibroblast growth factor (FGF) and type 13 transforming 
growth factor (TGFI3) (6, 14, 18, 28, 29, 32, 33, 38-40, 52, 
53). In the presence of these growth factors,  myoblasts fail 
to fuse or to express muscle-specific gene products.  Con- 
versely, reduction in the concentration  of these growth fac- 
tors below a critical  level results  in irreversible withdrawal 
from the cell cycle and terminal differentiation.  After fusion, 
muscle-specific genes become refractory to the inhibitory 
effects of polypeptide growth factors.  Little is known of the 
intracellular  pathways whereby polypeptide growth factors 
influence the muscle differentiation program or of the mech- 
anisms  responsible  for the  loss of sensitivity  of muscle- 
specific genes in myotubes to growth factors. 
The products of proto-oncogenes have been postulated to 
play important roles in regulation of cellular proliferation and 
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cell surface to the nucleus (3, 22, 50). As an initial step to- 
ward understanding the mechanisms involved in growth fac- 
tor-mediated regulation of myogenesis, we have chosen to 
examine  the  consequences  of autonomous  expression  of 
specific oncogenes on myogenic differentiation. Recently, 
Schneider  et  al.  reported  that  deregulated  expression  of 
c-myc,  the putative intranuclear mediator of growth factor 
signals, partially inhibited but did not prevent, induction of 
muscle-specific genes in the BC3H1 muscle cell line (49). 
In contrast, mutationally activated ras oncogenes conferred 
a phenotype on myoblasts similar to that elicited by FGF and 
TGFI~ and suppressed completely the ability of myoblasts to 
differentiate (41). 
The mammalian ras family consists of  the Harvey (H)-ras, 
Kirsten (K)-ras, and N-ras genes, each of which encodes a 
21-kD GTP-binding proteins localized to the cytoplasmic sur- 
face of the plasma membrane (for review, see reference 30). 
Ras proteins appear to participate in transduction of mito- 
genic signals by interacting with specific cell surface growth 
factor receptors  and other proximal elements in cascades 
triggered by growth factors (17, 27, 30, 37, 55, 59).  Termina- 
tion of transduced signals between receptors and enzyme ef- 
fectors is postulated to be achieved through hydrolysis of GTP 
by endogenous GTPase activity of normal ras proteins, ras 
genes bearing point mutations, generally at codons 12 or 61, 
have been isolated from a  wide range of tumors and have 
been shown to transform human and rodent cells (4, 30, 45, 
57, 58). These mutations do not influence the subcellular lo- 
calization of the proteins or their ability to bind guanine 
nucleotides, but in most cases result in diminished GTPase 
activity (12, 16, 34, 56).  The loss of GTPase activity of mu- 
tant ras proteins has been associated with persistent activa- 
tion of specific intracellular growth factor cascades and al- 
leviation of growth factor requirements. 
Previously, we reported that constitutive expression of the 
oncogenic forms of N- and H-ras prevented myoblast differ- 
entiation (41). Several important questions concerning the 
mechanism  for  ras-dependent  inhibition  of  myogenesis, 
however, were not amenable to experimental analysis in dif- 
ferentiation-defective cell lines that expressed ras constitu- 
tively. For example, it remained unclear whether the inhibi- 
tory effects of ms on differentiation were reversible, and if 
so,  whether the  kinetics for induction of muscle-specific 
genes would be accelerated or delayed after release of myo- 
blasts from ras-dependent repression. It was also unknown 
whether muscle-specific genes were susceptible to ras only 
during a specific period early in the differentiation program 
or whether these genes remained responsive to ras in termi- 
nally differentiated myotubes. The latter issue was of  particu- 
lar interest in light of observations that muscle-specific genes 
no longer respond to serum mitogens, FGF or TGFI3 after 
myoblast fusion (6,  14, 32, 33, 40). 
Here, we report that transfection of the C2 myoblast cell 
line with a mutationally activated N-ras gene linked to the 
steroid-inducible mouse mammary tumor virus long termi- 
nal repeat (MMTV-LTR), renders myoblasts sensitive to in- 
hibition of differentiation by dexamethasone. Suppression of 
the differentiated state by dexamethasone occurred in a dose- 
dependent manner and required the continual presence of  the 
steroid in the culture medium. Removal of dexamethasone 
led to fusion and induction of muscle-specific gene products 
with kinetics indistinguishable from control C2 myoblasts. 
The mechanism whereby ras inhibited differentiation did not 
require cell proliferation and was apparently not mediated by 
autocrine growth factors. In contrast to the ability of ms to 
prevent differentiation of myoblasts, induction of ras in ter- 
minally differentiated myotubes was without effect on myo- 
tube morphology or expression of muscle-specific genes. 
Together,  these results indicate that ras  inhibits myogenic 
differentiation through  a  highly  transient  and  reversible 
mechanism and that this ras-dependent pathway interferes 
with an early step in the process of muscle-specific gene acti- 
vation. In each of these respects, the mechanism for suppres- 
sion of differentiation by ras resembles the mechanism used 
by TGFI3 and FGF (6,  14, 32,  33, 40). 
Materials and Methods 
Cell Culture 
The mouse skeletal muscle cell line, C2 (60) was grown in DME containing 
20% FCS, as described (40). To initiate differentiation, cultures at ,080% 
confluence were transferred to DME containing 10%  horse serum (HS). 
Dexamethasone (Sigma Chemical Co., St. Louis, MO) was prepared as a 
0.1 mM stock in sterile deionized water and was added to culture media at 
the concentrations indicated. To obtain pure cultures of myotubes, confluent 
cultures that had been exposed to DME with 10% HS for at least 48 h were 
transferred to DME with 20%  FCS and 0.1  mM cytosine arabinoside for 
48 h. Aphidicolin (Sigma Chemical Co.) was stored as a  1 mg/ml stock in 
100%  ethanol and was added to a final concentration of 5  I~g/ml to DME 
containing 10% HS as an alternative method of obtaining pure myotube cul- 
tures. Cell numbers were determined with a Coulter Counter (Coulter Elec- 
tronics, Inc., Hialeah, FL). 
In experiments that required coculturing of C2 cells with CO25 cells, 
harriers of silicon grease ,02-mm wide were applied to the centers of 35-ram 
culture dishes. Cells of each type were plated at equivalent densities on op- 
posite sides of the barrier, which was of sufficient height to prevent exchange 
of media between the two sides. After cells had attached to the substratum, 
residual nonadherent cells were removed, the barrier was aspirated away 
such that only a thin line of silicon grease remained on the dish to separate 
the two cell types, and fresh medium with or without dexamethasone, as 
specified, was added to the cultures. Cultures were then placed on a rotating 
shaker at 60 rpm in a tissue culture incubator. After achieving 80% con- 
fluency, cultures were transferred to 10% HS and placed back on the shaker. 
At the indicated times, each cell type was harvested separately for CK assays 
and protein determination. 
Transfection and Isolation of  Dexamethasone-responsive 
Cell Lines 
Cultures of C2 cells in  10-cm culture dishes containing "05  ×  106 cells 
were  transfected by  calcium phosphate precipitation  (19)  with pSV2neo, 
which confers resistance to G418 as a selectable marker (51), and with the 
oncogenic form of N-ras containing a substitution of lysine for glutamine 
at amino acid 61 (4). The N-ras gene was under transcriptional control of 
the MMTV-LTR, conferring glucocorticoid inducibility to the gene. The 
details of this plasmid were described previously (35).  At  16-24 h  after 
transfection, cells were transferred from 1 10-cm dish to two 15-cm dishes 
and at 48 h after transfection 400 ~tg/ml of G418 (Gibco, Grand Island, NY) 
was added to the cultures in growth media. Individual colonies were isolated 
after 14 d and passaged into stable cell lines. Clonal cell lines were exposed 
to a  series of concentrations of dexamethasone from 10 nM to 2  ~tM and 
CK activity and the extent of fusion were determined. Cell lines that showed 
a dose-dependent inhibition or retardation of differentiation were selected 
and tested further. 
Assays  for CK Activity and ACh receptor 
Creatine kinase (CK) was assayed as described previously (38). Acetylcho- 
line receptors (AChR) were assayed by the specific binding of [125I]a-bun- 
garotoxin to cell monolayers (39). 
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by Western Transfer 
A mouse anti-ms p21 monoclonai antibody, 259, (Cetus Corp., Emeryville, 
CA) was used for quantitation of ms p21 protein (15).  Cell lysis and protein 
extraction were  carried out according to manufacturer's instructions and 
protein transfer was performed  as  described previously  (38).  Equivalent 
quantities of protein from cells under each condition were applied to the 
lanes. After incubation of nitrocellulose blots with the primary anti-ms p21 
antibody, an ~2SI-labeled rabbit anti-mouse secondary antibody was added. 
After subsequent washing, blots were exposed to Kodak X-AR5 film using 
intensifying screens.  Relative levels of p21  ms were quantitated by den- 
sitometry of autoradiographs. 
RNA Isolation and Northern Blot Hybridization 
RNA was prepared from cell cytoplasm by magnesium precipitation of poly- 
ribosomes (44).  The relative abundance of individual mRNAs was deter- 
mined  by  Northern  blot hybridization  followed  by  densitometry,  as  de- 
scribed previously  (52).  Equivalent quantities of RNA  from cells under 
each condition were applied to the lanes. N-ras mRNA was measured using 
a 665 base-pair Sal I/Eco RI fragment from a human N-ras cDNA contain- 
ing exons II, III and IV (57, 58). DNA probes were labeled with 32p by the 
method of Feinberg and Vogelstein (10). 
Results 
N-ras Reversibly Inhibits Myoblast Fusion 
When maintained  at  subconfluent densities  in  DME  with 
20% FCS, C2 myoblasts proliferate and exhibit none of the 
biochemical or morphological manifestations of the myo- 
genic phenotype (25,  40, 41,  60).  The onset of differentia- 
tion, after transfer of cultures at 80 % confluence to medium 
with 10% HS (fusion-promoting medium), is marked by the 
appearance of multinucleate myotubes and the accumulation 
of muscle-specific gene products such as MCK and the ACh 
receptor. 
Constitutive expression of transforming ras genes com- 
pletely inhibits fusion and induction of muscle-specific gene 
products in C2 cells (41). To extend our understanding of the 
mechanisms involved in ras-dependent inhibition of myogen- 
esis, C2 cells were transfected with a human N-ras gene, ac- 
tivated by a missense mutation at position 61 (4). Transcrip- 
tion of N-ras was controlled by the MMTV-LTR, rendering 
the gene inducible by dexamethasone,  ras genes were co- 
transfected with the selectable marker pSV2neo, which con- 
fers resistance to the neomycin analog, G418. Colonies aris- 
ing from the transfection were screened initially by adding 
fusion-promoting medium containing 2 lxM dexamethasone. 
Of a total of 26 independent colonies examined, 10 failed to 
form myotubes when exposed to dexamethasone under fu- 
sion-promoting  conditions.  These  dexamethasone-respon- 
sive  colonies were  isolated  and  passaged  into  stable  cell 
lines. Subsequent analysis revealed that seven of the cell lines 
fused  normally  in  the  absence  of dexamethasone but re- 
mained as mononucleate cells in the presence of dexametha- 
sone. The remaining three of the clones were either partially 
or completely differentiation-defective. 
In our previous studies using constitutively expressed ras 
oncogenes, we found that the effects of ras were dominant 
and that virtually all clones bearing mutant ras genes were 
unable to differentiate (41). Therefore, in the present study, 
we limited our analysis to clones that showed dose-depen- 
dent inhibition of morphological differentiation in response 
to dexamethasone. Clones that differentiated in the presence 
ofdexamethasone were considered to lack functional steroid- 
inducible ras genes, whereas clones that never differentiated 
were assumed to express the transfected ras oncogene con- 
stitutively or to represent clones that originated from dif- 
ferentiation-defective cells in the original population. 
Fig. 1 shows the morphology of a representative clonal cell 
line, designated CO25, bearing the steroid-inducible N-ras 
oncogene, under a  series of culture conditions.  In growth 
medium,  CO25  cells were morphologically indistinguish- 
able from nontransfected C2  myoblasts (data not shown). 
Transfer of cultures at 80% confluence to fusion-promoting 
medium led to formation of myotubes with kinetics identical 
to normal C2 cells (Fig.  1 A). In contrast, addition of 100- 
2,000 nM dexamethasone to fusion-promoting medium re- 
suited in a complete block in the ability of CO25 myoblasts 
to form myotubes (Fig.  1 B). The inhibitory effects of dexa- 
Figure 1. Effects of dexamethasone on morphology of myoblasts bearing steroid-inducible N-ras oncogenes. The CO25 cell line, bearing 
the steroid-inducible N-ras oncogene, was cultured in DME with 20% FCS. After achieving 80% confluency, cultures were transferred 
to fusion-promoting medium for 5 d (A). A separate set of cultures was treated identically but was exposed to 500 nM dexamethasone 
48 h before transfer to fusion-promoting medium containing dexamethasone (B). After 3 d in fusion-promoting medium containing dexa- 
methasone, cultures shown in Panel B were transferred to fresh medium without dexamethasone for 3 d (C). 
Gossett et al.  ras-Dependent Inhibition of Myogenesis  2129 B  A 
~X 
2~ 
2O0O 
1~  ,-OEX 
1234 
c 
4O0O 
35O0  -OEX 
3000 
2OOO 
1500 
1000 
5OO 
2  4  6 
1  2  3  4 
D 
2  4  6 
60 
'40 
6 
t~ 
lO 
.o 
o  so  ..k 
Time(d) 
Figure 2. Expression of CK activity and ACh receptors in normal 
myoblasts and in myoblasts bearing steroid-inducible N-ras on- 
cogenes. Normal C2 cells (A and B) or CO25 cells (C and D), bear- 
ing the steroid-inducible N-ras oncogene, were cultured in DME 
with 20% FCS. After achieving 80% confluency (day 0), cultures 
were transferred to fusion-promoting medium in the presence (o) 
or absence (e) of 500 nM dexamethasone. A separate set of CO25 
cultures was exposed to 500 nM dexamethasone for 48 h before ex- 
posure  to  fusion-promoting medium  containing dexamethasone 
(A). CK activity and ACh receptors were assayed on consecutive 
days. 
methasone on fusion were not observed in normal C2 myo- 
blasts (data not shown). Maintenance of CO25 cells in fusion- 
promoting medium with dexamethasone for up to 7 d failed 
to result in detectable formation of multinucleate myotubes, 
indicating that dexamethasone inhibited rather than delayed 
the morphological alterations associated with terminal dif- 
ferentiation. In the presence of dexamethasone at concentra- 
tions lower than 100 nm, intermediate levels of myoblast fu- 
sion were observed (data not shown). 
To determine whether the inhibitory effects of dexametha- 
sone on morphological differentiation were reversible, fu- 
sion-blocked CO25 myoblasts, maintained in the presence of 
fusion-promoting medium with dexamethasone for 3 d, were 
transferred to fusion-promoting medium without dexametha- 
sone.  As  shown in Fig.  1  C,  these cultures formed large 
branching myotubes within 3 d after removal of dexametha- 
sone. Thus, the inhibitory effects of dexamethasone on mor- 
phological  differentiation of myoblasts bearing  steroid-in- 
ducible ras oncogenes were fully reversible and required the 
continual presence of the steroid in the culture medium. 
Transforming N-ras Oncogenes Inhibit Muscle-specific 
Gene Expression 
To determine whether muscle-specific genes in CO25 cells 
were subject to regulation by dexamethasone, undifferenti- 
ated cultures in growth medium were exposed to 500 nM 
dexamethasone for 48 h before transfer to fusion-promoting 
medium,  or were transferred directly to fusion-promoting 
medium containing the steroid. In the absence of dexametha- 
sone, the muscle-specific gene products, CK and ACh recep- 
tor, were induced in a similar manner in normal C2 cells and 
in CO25 cells (Fig. 2). In the presence of dexamethasone, 
however, induction of CK and ACh receptors was inhibited 
dramatically in CO25  cells.  Suppression of differentiation 
by dexamethasone occurred rapidly as demonstrated by the 
nearly complete inhibition of expression of muscle-specific 
gene products in cultures exposed to fusion-promoting me- 
dium with dexamethasone without pretreatment with the ste- 
roid (Fig. 2, C and D). Induction of CK activity and ACh 
receptors in C2 myoblasts was not inhibited by dexametha- 
sone (Fig. 2, A and B). Together, these results demonstrate 
that the morphological and biochemical events associated 
with myogenesis become sensitive to inhibition by dexameth- 
asone after transfection of myoblasts with a steroid-inducible 
ras oncogene. 
1ime Course for Induction of N-ras Protein and mRNA 
by Dexamethasone 
The ability  of dexamethasone to  inhibit differentiation of 
CO25 myoblasts with no apparent lag (Fig. 2) suggested that 
the N-ras protein accumulated relatively rapidly in response 
to steroid induction. To determine the kinetics for ras induc- 
tion, CO25 myoblasts were exposed to 500 nM dexametha- 
sone for a series of times, cell extracts were prepared, and 
levels of p21  ras protein were quantitated by Western blot 
analysis using the anti-ras monoclonal antibody, 259 (15). 
In the absence of dexamethasone, a 21-kD polypeptide that 
comigrated with purified ras protein, was evident in CO25 
cells (Fig. 3 A) and in C2 myoblasts (data not shown). Be- 
cause the antibody used for these studies recognizes the en- 
dogenous proto-oncogenic forms of H-ras and N-ras from 
mouse, we conclude that this band represents one or both of 
these normal ras proteins. We do not know the identity of the 
polypeptide of  higher molecular weight that is sometimes de- 
tected by the anti-ras antibody. After addition of dexametha- 
sone to CO25 cells, the p21 polypeptide began accumulating 
~3 to 5 h after exposure of cells to the steroid and continued 
to increase over a period of 48 to 60 h. The maximum steady 
state level achieved by exogenous p21 ras was four- to fivefold 
higher than the level of the endogenous ras proteins (Fig. 3, 
A and B). 
The kinetics for induction of N-ras mRNA also were de- 
termined by Northern blot hybridization using a 32p-labeled 
human N-ras cDNA. The hybridization probe used for this 
experiment hybridizes only to human N-ras transcripts and 
therefore permits accurate measurement of exogenous N-ras 
mRNA expression without complications from the endoge- 
nous proto-oncogenic mRNA species. As shown in Fig. 3 C 
this probe hybridized to an mRNA species of 2.2 kb, corre- 
sponding to exogenous N-ras mRNA (21, 35). The kinetics 
of induction of N-ras mRNA were similar to those of p21 
N-ras protein. The pattern of expression of N-ras mRNA in 
response to dexamethasone was similar in myoblasts growing 
in 20% FCS (Fig. 3 C) and in differentiating cultures after 
2 d in  10%  HS (data not shown). 
It is of interest to note that steroid induction of N-ras via 
the MMTV-LTR occurred with delayed kinetics in C2 cells 
compared with previous reports in 3T3 cells (26,  43).  We 
also observed little or no feed-back inhibition of ras expres- 
sion as was observed in 3T3 cells transfected with MMTV- 
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trasting pattern of expression of N-ras  in C2  myoblasts is 
unclear, but may reflect a lower level of glucocorticoid recep- 
tors in these cells,  although this has not yet been tested. 
Figure 3. Induction of N-ras protein and mRNA by dexamethasone 
in myoblasts bearing steroid-inducible N-ras oncogenes. The CO25 
cell line,  bearing  the steroid-inducible  N-ras oncogene,  was cul- 
tured in DME with 20% FCS. 500 nM dexamethasone was added 
to the cultures at time 0 and cells were harvested at the indicated 
times after exposure to the steroid.  (A) levels of p21N-~s were de- 
termined by Western blot analysis usin~ anti-p21 antibody, 259, as 
described  in Materials and Methods.  Purified p21 ras protein was 
used as a standard in the left lane. (B) levels of N-ras protein from 
A were quantitated  by densitometry  of the autoradiographs.  (C) 
Levels of exogenous N-ras mRNA were determined  by Northern 
blot analysis at the indicated times. The position of 18 S ribosomal 
RNA is indicated. 
Dose-dependent Induction of  N-ras and Inhibition 
of  Differentiation by Dexamethasone 
It was of interest to correlate directly the levels of N-ras ex- 
pression with the extent of differentiation and thereby deter- 
mine the minimum level of ras required to completely extin- 
guish the differentiated phenotype. The dose dependence for 
inhibition of differentiation of CO25 cells by dexamethasone 
is shown in Fig. 4 A. Partial inhibition of CK expression was 
observed at concentrations  of dexamethasone as  low as  5 
nM.  The ID50 for dexamethasone was •7  nM,  with maxi- 
mum inhibition occurring at 100 nM. These results indicate 
that ras does not inhibit myogenesis through an absolute all- 
or-none event. Instead, it appears that the effects of ras oc- 
cur in a graded manner through a concentration-dependent 
mechanism. 
The dose-dependence on dexamethasone of N-ras mRNA 
induction  was also analyzed in  CO25  cultures  exposed to 
varying concentrations of the steroid for 72 h. As shown in 
Fig.  4 B,  N-ras  mRNA  was detectable in  the presence of 
dexamethasone at concentrations as low as 5 nM.  Maximal 
levels of N-ras mRNA expression occurred at 25 to 100 nM 
dexamethasone.  Comparison  of the  dependence  on  dexa- 
methasone of N-ras mRNA accumulation with the extent of 
inhibition of differentiation, showed an inverse relationship 
(Fig.  4  C);  the  EDso  for both  processes  was  7  nM  with 
maximal responses occurring between 25  and  100 nM. 
Reversibility of  Ras-dependent Inhibition 
of Differentiation 
To determine whether the inhibitory effects of ras on muscle- 
specific gene expression were reversible, CO25  cells were 
maintained in fusion-promoting medium containing 500 nM 
dexamethasone for 3 d and were subsequently transferred to 
fresh  fusion-promoting  medium  lacking  the  steroid.  As 
shown in Fig. 5, removal of dexamethasone from differentia- 
tion-inhibited CO25 cells led to appearance of CK and ACh 
receptors with kinetics indistinguishable  from those of the 
initial  induction of these muscle gene products in C2 cells 
or in non-dexamethasone-treated CO25 cells. These results 
indicate that the inhibitory effects of ras on muscle-specific 
gene expression are readily reversible and that prolonged ex- 
pression of ras in myoblasts neither accelerates nor delays 
subsequent induction of muscle-specific gene products after 
release of myoblasts from ras-dependent  inhibition. 
Terminal Differentiation After Release 
from ras-dependent Repression Does Not Require 
a Round of  DNA Synthesis 
It was  of interest  to  determine  whether  CO25  myoblasts, 
released from ras-dependent  inhibition of differentiation by 
removal of dexamethasone, required a round of cell division 
to be reprogrammed before induction  of the  differentiated 
phenotype. To address this question, we tested whether inhi- 
bition  of DNA  synthesis  interfered  with  differentiation of 
CO25  cells  after transfer  from fusion-promoting medium 
containing dexamethasone to fresh medium lacking the ste- 
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Figure 4.  Dose-dependent inhibition  of differentiation  and induc- 
tion of N-ras mRNA by dexamethasone.  The CO25 cell line, bear- 
ing the steroid-inducible  N-ras oncogene, was cultured  in DME 
with 20%  FCS. After achieving 80% confluency (day 0), cultures 
were transferred  to fusion-promoting medium containing a range of 
concentrations  of dexamethasone.  (A) CK activity  was assayed on 
consecutive days after exposure to the steroid.  (B) Levels of exoge- 
nous N-ras mRNA were determined by Northern blot analysis after 
exposure to fusion-promoting media containing dexamethasone  for 
72 h. (C) Levels of N-ras mRNA expression in response to dexa- 
methasone were determined by densitometry of the Northern blot 
shown in B. CK activity after exposure of  CO25 cells to dexametha- 
sone for 72 h was obtained from A. Levels of N-ras mRNA are ex- 
pressed relative  to the level in the presence of 25 nM dexametha- 
sone,  which was assigned a value of 100%. Levels of CK activity 
are expressed  relative to the level in control cultures  without dexa- 
methasone,  which was assigned a value of 100%. 
roid. In the presence of 5  ~tg/ml  aphidicolin,  which inhibits 
DNA synthesis, fusion (data not shown) and induction of CK 
activity occurred normally after removal of dexamethasone 
from differentiation-inhibited  cultures  (Fig.  6).  Similar  re- 
sults  were  obtained  in  the  presence  of 0.1  mM  cytosine 
arabinoside,  which  eliminates  replicating  cells  (data  not 
shown). It can be concluded, therefore, that a round of DNA 
synthesis is not required  for myoblasts to overcome the in- 
hibitory effects of ras on differentiation. 
The N-ras Oncogene Does Not Abrogate 
the Requirement  for Growth Factors to Divide 
Differentiation  of  skeletal  myoblasts  depends  absolutely 
upon cessation  of cell  division.  Because  transforming  ras 
genes have been  reported  to release  some cell  types from 
their dependence on exogenous growth factors to divide,  it 
was important to determine whether the failure of CO25 cells 
to differentiate in the presence of dexamethasone might be 
attributable  to continued proliferation  of these  cells  in fu- 
sion-promoting medium. As shown in Fig. 7, neither the rate 
of cell  division  in  20%  FCS  nor  the  saturation  density 
achieved by CO25 cells were affected appreciably by dexa- 
methasone.  Moreover,  dexamethasone-treated  CO25  cells 
withdrew  from the  cell  cycle at  subconfluent  densities  in 
medium with 0.5%  FCS in a  manner identical to C2 myo- 
blasts.  These experiments were performed in medium con- 
raining 0.5%  FCS rather than 10%  HS because HS contains 
a low level of mitogenic activity that supports a slow rate of 
growth  of  C2  myoblasts  at  low  densities.  To  determine 
whether CO25 cells were able to stop dividing completely 
in the presence of dexamethasone it was necessary to analyze 
their  growth rate  under conditions  in  which there  was  no 
proliferation  in  control  cultures.  The  inhibitory  effects  of 
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Figure 5. Reversibility of the differentiation-defective  phenotype of 
myoblasts  bearing steroid-inducible  N-ms oncogenes.  The CO25 
cell  line,  bearing the steroid-inducible  N-ras oncogene, was cul- 
tured in DME with 20% FCS. After achieving 80% confluency (day 
0),  cultures  were transferred  to fusion-promoting medium in the 
presence (o) or absence (e)  of 500 nM dexamethasone  (DEX). 
Half of the cultures maintained  in dexamethasone  were transferred 
to fresh fusion-promoting medium without dexamethasone  on day 
3 (A). CK activity and ACh receptors  were assayed on consecutive 
days. 
dexamethasone  on differentiation  of CO25  cells  were also 
observed in the presence of 0.5 % FCS (data not shown). We 
conclude that dexamethasone-dependent inhibition of differ- 
entiation of CO25 cells occurs through a mechanism inde- 
pendent of continuous cell proliferation. These results do not 
rule out the possibility,  however, that ras may confer subtle 
alterations in sensitivity to specific growth factors that would 
not be detectable  by the assays employed here. 
ras Does Not Inhibit Myogenic Differentiation through 
An Autocrine Mechanism 
The  ability  of ras oncogene proteins  to  inhibit  myogenic 
differentiation could be due to direct activation by ras of an 
intracellular  pathway  that  interferes  with  muscle-specific 
gene expression.  Alternatively, ras could prevent myogene- 
sis indirectly through an autocrine mechanism involving re- 
lease of an inhibitory growth factor. The latter possibility is 
particularly relevant, in light of reports that some ras-trans- 
formed cell types secrete transforming growth factors (1, 54), 
which are known to inhibit myogenesis (14, 33, 40). To dis- 
tinguish  between  these  possibilities,  normal  C2  cells  and 
CO25 cells were cultured on opposite sides of a barrier that 
allowed free exchange of medium between the two cell types. 
Cultures  were maintained  in growth medium containing 2 
lxM  dexamethasone for 48 h  and were subsequently  trans- 
ferred to fusion-promoting medium with the steroid for 3 d. 
Cells were then harvested separately from each side of the 
permeable barrier and CK activity was assayed.  As shown 
in  Fig.  8,  differentiation  of C2 cells  was  not affected  sig- 
nificantly by the presence of medium conditioned by dexa- 
methasone-treated  CO25 cells.  These results argue against 
the involvement of autocrine factors in ras-dependent  inhibi- 
tion of differentiation and suggest that ras activates an intra- 
cellular cascade that interferes directly with the differentia- 
tion program. 
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Figure 6. Effects of inhibitors of DNA synthesis on induction of OK 
activity following removal of dexamethasone  from myoblasts bear- 
ing steroid-inducible  N-ras oncogene. The CO25 cell line, bearing 
the steroid-inducible  N-ras oncogene, was cultured in DME with 
20%  FCS.  After achieving 80%  confluency,  cultures were trans- 
ferred to fusion-promoting medium in the presence (o) or absence 
to) of 500 nM dexamethasone  (DEX). After 3 d, dexamethasone- 
treated cultures were transferred  to fresh fusion-promoting medium 
lacking the steroid,  but containing 5 mM aphidicolin (A) or no ad- 
dition (m). CK activity was determined on consecutive days. 
Induction of  N-ras in Terminally 
Differentiated Myotubes Does Not Extinguish 
Muscle-specific Gene Expression 
The ability to modulate N-ras expression in CO25 cells with 
dexamethasone  made  it possible  to investigate whether  in- 
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Figure 7.  Effects of dexamethasone  on proliferation of myoblasts 
beating steroid-inducible  N-ras oncogenes. Normal C2 cells (A) or 
CO25  cells  (B),  bearing  the  steroid-inducible  N-ras oncogene, 
were cultured in DME with 20% FCS. On day 1, cultures were ex- 
posed to DME with 20% or 0.5% FCS in the presence (A) or ab- 
sence (o) of 500 nM dexamethasone (DEX),  as  specified.  Cell 
numbers  were  determined  on consecutive days  using a  Coulter 
Counter.  (Open symbols), 20% FCS; (closed symbols), 0.5 % FCS. 
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urh conditioned by myoblasts 
bearing steroid inducible N-ms 
oncogenes  on  differentiation 
of normal  C2  cells.  Normal 
C2 cells and CO25 cells, bear- 
ing the steroid inducible N-ras 
oncogene, were plated at equiv- 
alent densities in 35-mm cul- 
ture dishes on opposite  sides 
of a permeable  barrier.  Cul- 
tures were maintained in DME 
with  20%  FCS  and  2  p.M 
dexamethasone (DEX). After 
achieving 80% confluency, cul- 
tures  were  transferred  to  fu- 
sion-promoting  medium  and 
dexamethasone. 3 d later cells 
were harvested separately from 
each half of the dish and CK 
activity was determined. 2 ~tM 
dexamethasone  was  used  in 
these  experiments  to  ensure  maximum persistent  expression  of 
N-ras in CO25 cells throughout the course of the experiment. This 
high level of dexamethasone does not have adverse effects on cell 
viability. 
duction of N-ras in terminally differentiated myotubes was 
sufficient to extinguish expression of muscle-specific genes. 
Preliminary  experiments  indicated  that  myotube  cultures 
that contained a significant percentage of nuclei in unfused 
myocytes showed a decline in expression of CK activity and 
mRNA in response to dexamethasone. We believe this inhibi- 
tory response may reflect the down-regulation of muscle-spe- 
cific gene products in partially differentiated mononucleate 
cells,  since fusion is not a prerequisite for muscle-specific 
gene expression in C2 cells (Hu, J. S., and E. N. Olson, un- 
published  results).  Our  primary purpose  was  to  examine 
whether  muscle-specific genes in  terminally differentiated 
myotubes  were  susceptible  to  ras-dependent  repression. 
Therefore, to obtain cultures of pure myotubes, CO25 cells 
were cultured in fusion-promoting medium for 2 d, at which 
time large, branching myotubes were clearly visible.  Non- 
fused myocytes were then eliminated from the  cultures by 
stimulation with growth medium containing 20%  FCS and 
0.1 mM cytosine arabinoside for 2 d. Pure cultures of termi- 
nally differentiated myotubes were exposed subsequently to 
1 IxM dexamethasone and CK activity was assayed at 24-h 
intervals  after addition  of the  steroid.  Under  these condi- 
tions, CK activity (Fig. 9) and MCK mRNA (data not shown) 
continued to increase after addition of dexamethasone to cul- 
tures of CO25  myotubes. The morphology of CO25  myo- 
tubes also remained unchanged in the presence of dexameth- 
asone. 
The failure of ras to suppress muscle-specific gene expres- 
sion in myotubes cannot be attributed to a loss of responsive- 
ness of the transfected ras gene to steroids because N-ras 
mRNA was induced in myotubes in response to dexametha- 
sone (Fig. 10). We did observe, however, that 1,000 nM dexa- 
methasone  was required  to  induce  ras expression in  myo- 
tubes to levels comparable to that induced  in myoblasts by 
100 nM dexamethasone (data not shown). Together these re- 
sults demonstrate muscle-specific genes are susceptible to 
ras-dependent repression during the early stages of the dif- 
ferentiation process. However, in pure cultures of terminally 
differentiated myotubes muscle-specific genes appear to be- 
come refractory to the inhibitory signals generated by trans- 
forming ras proteins. 
Discussion 
The transition  of certain  types of myoblasts to  terminally 
differentiated myotubes has been shown previously to be in- 
hibited by TGFI3 and FGF through a mechanism independent 
of cell proliferation (6,  14, 28,  29,  33, 40, 52). Inhibition of 
fusion and muscle-specific gene expression requires the con- 
tinual presence of these growth factors in the extracellular 
milieu and is rapidly reversible after their removal. These 
results are consistent with the notion that inhibition of myo- 
genesis by TGFI3 and FGF requires continuous occupancy of 
their respective cell surface receptors and involves an intra- 
cellular signal (or signals) that is extremely short-lived. 
In an  effort to identify  the  intracellular  signalling  path- 
way(s) used by TGFI3 and FGF to regulate myogenesis, we 
have introduced  a  series of mutationally activated ras on- 
cogenes  into  myoblasts and  have investigated whether  the 
proteins encoded by these oncogenes might confer a pheno- 
type on myoblasts similar to that elicited by TGFI3 and FGE 
ras oncogenes were selected for these studies because ras 
proteins are localized to the plasma membrane where they 
are  believed  to  function  at  an  early  step  in  intracellular 
growth factor cascades by transducing signals between spe- 
cific cell surface growth factor receptors and intracellular en- 
zyme effectors (2,  11, 27,  30,  35,  37,  55,  59).  Recently, we 
reported that transfection of C2 cells with mutationally acti- 
vated N- or H-ras oncogenes, under constitutive transcrip- 
tional  control,  completely  inhibited  the  molecular  events 
associated with myogenic differentiation (41). Similar inhibi- 
tion  of differentiation by  ras  was observed in  the  BC3H1 
muscle cell line (5, 46,  Klein, D. J., and A. Connally, per- 
sonal communication). 
In the present study, we have extended these previous ob- 
servations by constructing myoblast cell lines in which the 
entire developmental program is subject to negative control 
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Figure 9. Effects of dexameth- 
asone on CK activity in termi- 
nally differentiated myotubes. 
CO25  cells  were  allowed to 
achieve  80%  confluency and 
were  transferred  to  medium 
with  10%  HS for 48 h.  Cul- 
tures were then fed with medi- 
um containing 20% FCS and 
0.1  mM cytosine arabinoside 
to eliminate unfused cells. Af- 
ter 48 h  in cytosine arabino- 
side, half of the cultures were 
exposed to 1 IxM dexametha- 
sone and CK activity was de- 
termined on consecutive days. 
Time 0  on the  graph  repre- 
sents the time in which dexamethasone was added to cultures of 
pure myotubes which had initiated differentiation 4 d earlier. 
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in terminally differentiated myotubes. CO25 cells were allowed to 
achieve 80% confluency and were transferred to medium with 10% 
HS for 48 h. Cultures were then fed with medium containing 20% 
FCS and 0.1 mM cytosine arabinoside to eliminate unfused cells. 
Dexamethasone (1 IxM) was also added to the cultures at the time 
of addition of cytosine arabinoside. At the indicated times, RNA 
was isolated and steady state levels of N-ms mRNA were deter- 
mined by Northern blot analysis. Levels of N-ras mRNA in myo- 
blasts exposed to  1 IJ.M dexamethasone and in myotubes in the 
absence of the steroid are also shown. 
by dexamethasone. These myoblast cell lines, bearing ste- 
roid-inducible  N-ras  oncogenes,  permit  cell  cycle  with- 
drawal  to  be  reversibly dissociated  from  muscle-specific 
gene induction and  allow  fine-tuning of the differentiated 
phenotype in a manner not previously possible. The precise 
control over the differentiation program afforded by these 
cell lines  should facilitate detailed analysis of the mecha- 
nisms whereby growth factor signalling cascades impinge on 
muscle-specific genes. 
The results of the present study extend our understanding 
of the mechanism for ms-dependent regulation of myogene- 
sis in at least four important respects. First,  suppression of 
differentiation of myoblasts bearing steroid-inducible ras on- 
cogenes was demonstrated to be rapidly reversible after with- 
drawal of dexamethasone. This observation indicates that the 
ras-dependent phenotype requires the continual presence of 
ras to be maintained and implies that interference with the 
differentiation program by ras proteins requires the persis- 
tent  transduction  of highly  transient  intracellular  signals. 
Second, the degree of differentiation of myoblasts bearing 
steroid-inducible ras genes was a titratable function of N-ras 
expression with partial inhibition of fusion and induction of 
muscle-specific genes occurring at low levels of ras.  These 
results indicate the ms does not exert an all-or-none effect on 
the differentiation program, but rather, elicits a graded re- 
sponse proportional to the level of ras expression. Third, af- 
ter release of myoblasts from ras-dependent  inhibition, dif- 
ferentiation proceeded with normal kinetics, suggesting that 
ras arrests myoblasts at an early, rather than late step in the 
pathway toward differentiation. Induction of differentiation 
after release from ms-dependent inhibition also was shown 
to occur in the absence of an additional round of DNA syn- 
thesis,  indicating that myoblasts do not need to be repro- 
grammed during a quantal cell cycle to overcome the differ- 
entiation-defective  phenotype  conferred  by  ras.  Finally, 
induction of N-ras  failed to down-regulate muscle-specific 
genes in terminally differentiated myotubes. In each of these 
respects, the effects of oncogenic ms proteins on myogenesis 
resemble the effects of TGFI3 and FGE 
Several transformed cell types have been reported to se- 
crete transforming growth factors (1, 54). Therefore, to test 
the possibility that ras-dependent  inhibition of myogenesis 
might be mediated by an autocrine growth factor similar, or 
identical,  to  TGFI3 or  FGF,  the ability of ras-transfected 
myoblasts to transfer their phenotype to normal myoblasts 
through culture medium was examined. No evidence for au- 
tocrine  interactions  between  ras-transformed  and  normal 
myoblasts was detectable. Thus, we conclude that oncogenic 
ras  proteins directly transduce an intracellular signal that 
operates in an antagonistic manner to the normal develop- 
mental signals that initiate myogenesis. It should be empha- 
sized that ras proteins do not function directly as muscle- 
specific gene repressors. Instead, these proteins most likely 
activate an intracellular pathway that culminates in repres- 
sion of the differentiation program. 
What type of mechanisms might be responsible for ras-de- 
pendent inhibition of myogenic differentiation and how many 
intermediate steps may be involved? ras proteins are local- 
ized to the plasma membrane where they are postulated to 
function at an early step in the pathway for transduction of 
intracellular growth  factor signals.  Mutationally  activated 
ras proteins have been reported to substitute for exogenous 
growth factors and to persistently activate intracellular sig- 
nalling pathways that may normally be modulated by proto- 
oncogenic ras proteins (30). In light of the similarities be- 
tween the effects of TGFI~, FGF and ras on myogenesis, it 
is tempting to speculate that signalling pathways similar or 
identical to those activated by TGFfl and FGF might be am- 
plified in myoblasts bearing oncogenic ms genes. In this re- 
gard, several of the early events associated with growth fac- 
tor receptor occupancy have been shown to be activated by 
oncogenic ras proteins. For example, microinjection of fibro- 
blasts with oncogenic ras proteins or transfection with ras 
genes leads to increased activity of phospholipases A2 and 
C, which modulate arachidonate release and phosphatidyl- 
inositol turnover, respectively (2,  13, 47, 59).  ras oncogene 
proteins also have been reported to lead to an increase in 
intracellular pH, due to stimulation of the amiloride-sensi- 
tive Na+/H  ÷ exchange (20).  Finally,  ras  transformed cells 
have been demonstrated to  exhibit increased rates of gly- 
colysis and hexose transport which may contribute to a gen- 
eralized alteration in cellular metabolism (48).  The poten- 
tial involvement of one or more of these biochemical events 
in ras-dependent repression of myogenesis is currently under 
investigation. 
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been shown by Hauschka and coworkers to be preceded by 
down-regulation of cell surface EGF and FGF receptors (31, 
42).  A  similar pattern of regulation has been observed for 
TGFI~ receptors during fusion of C2 and L6A1 myoblasts (8). 
This loss of cell surface growth factor  receptors has been 
postulated  as a  mechanism  to account  for the  inability  of 
growth factors  to suppress muscle-specific gene expression 
in myotubes.  Because  ras proteins are believed to function 
at a post-receptor step in growth factor cascades, it was pos- 
sible to use CO25 cells to investigate  whether muscle-spe- 
cific genes in myotubes remained susceptible to repression 
by  intracellular  growth signals.  The results  reported here, 
which show that pure  myotubes  are  insensitive  to  signals 
generated by ras proteins, suggest that irreversible activation 
of muscle-specific genes in myotubes may not result exclu- 
sively from down-regulation of growth factor receptors.  The 
nature  of the  molecular  events  that  place  muscle-specific 
gene expression in myotubes beyond the control of ras re- 
main to be established. 
The consequences of expression of oncogenes encoding 
proteins presumed to function at early steps in intracellular 
growth  factor  cascades  have  been examined previously  in 
cultures of primary myoblasts (9, 23, 24, 36). These studies 
demonstrated  that v-src and v-erbB,  which encode tyrosine 
protein kinases, prevent the molecular events associated with 
myogenesis.  Like the effects of ras reported  here, these on- 
cogene products  prevented  differentiation  through  a mecha- 
nism independent of cell proliferation. It remains to be deter- 
mined whether tyrosine kinases and mutationally  activated 
ras proteins function through  the same, or through  parallel 
pathways to elicit their effects on the differentiation  program. 
Myoblast cell lines, modified by incorporation of exoge- 
nous oncogenes, offer the opportunity  to dissect the mecha- 
nisms  whereby  intracellular  signals  generated  at  the  cell 
surface culminate in alterations of gene expression. In the fu- 
ture, it will be particularly  interesting  to determine whether 
ras functions in the same intracellular  pathway activated  by 
TGFI~ and FGF or whether these regulators  of myogenesis 
utilize separate pathways that converge at a downstream step 
that governs the differentiation  program. 
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